Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer. Design: Pragmatic, cluster randomised trial. Setting: 20 cancer centres in Ontario, Canada, allocated by covariate constrained randomisation to remote management of toxicities or routine care. Participants: All patients starting adjuvant or neoadjuvant chemotherapy for early stage breast cancer at each centre. 25 patients from each centre completed patient reported outcome questionnaires. Interventions: Proactive, standardised, nurse led telephone management of common toxicities at two time points after each chemotherapy cycle. Main outcome measures: The primary outcome, cluster level mean number of visits to the emergency department or admissions to hospital per patient during the whole course of chemotherapy treatment, was evaluated with routinely available administrative healthcare data. Secondary patient reported outcomes included toxicity, self-efficacy, and quality of life. Results: Baseline characteristics of participants were similar in the intervention (n=944) and control arms (n=1214); 22% were older than 65 years. Penetration (that is, the percentage of patients who received the intervention at each centre) was 50-86%. Mean number of visits to the emergency department or admissions to hospital per patient was 0.91 (standard deviation 0.28) in the intervention arm and 0.94 (0.40) in the control arm (P=0.94); 47% (1014 of 2158 patients) had at least one visit to the emergency department or a hospital admission during chemotherapy. Among 580 participants who completed the patient reported outcome questionnaires, at least one grade 3 toxicity was reported by 48% (134 of 278 patients) in the intervention arm and by 58% (163 of 283) in the control arm. No differences in self-efficacy, anxiety, or depression were found. Compared with baseline, the functional assessment of cancer therapy trial outcome index decreased by 6.1 and 9.0 points in the intervention and control participants, respectively. Conclusions: Proactive, telephone based management of toxicities during chemotherapy did not result in fewer visits to the emergency department or hospital admissions. With the rapid rise in remote care because of the covid-19 pandemic, identifying scalable strategies for remote management of patients during cancer treatment is particularly relevant. Trial registration: ClinicalTrials.gov NCT02485678 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W., & Herzberg, P. Y. (2008) · Medical Care · doi:10.1097/mlr.0b013e318160d093 · Cited by 4,527
Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., Rogak, L., Bennett, A. V., Dueck, A. C., Atkinson, T. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0830 · Cited by 2,593
A conceptual framework for implementation fidelity
Carroll, C., Patterson, M., Wood, S., Booth, A., Rick, J., & Balain, S. (2007) · Implementation Science · doi:10.1186/1748-5908-2-40 · Cited by 2,559
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy
Absolom, K., Warrington, L., Hudson, E., Hewison, J., Morris, C., Holch, P., Carter, R., Gibson, A., Holmes, M., Clayton, B., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02015 · Cited by 311
Kearney, N., McCann, L., Norrie, J., Taylor, L., Gray, P., McGee-Lennon, M., Sage, M., Miller, M., & Maguire, R. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-008-0515-0 · Cited by 263
A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries
Bhasin, S., Gill, T. M., Reuben, D. B., Latham, N. K., Ganz, D. A., Greene, E. J., Dziura, J., Basaria, S., Gurwitz, J. H., Dykes, P. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002183 · Cited by 228
Mc Cord, K. A., Ewald, H., Agarwal, A., Glinz, D., Aghlmandi, S., Ioannidis, J. P. A., & Hemkens, L. G. (2021) · BMJ · doi:10.1136/bmj.n450 · Cited by 61
Cited by
Akingbade, O., Nguyen, K. T., & Chow, K. M. (2023) · Journal of Clinical Nursing · doi:10.1111/jocn.16533 · Cited by 35
Fang, H., Sun, Y., Yu, D., & Xu, Y. (2024) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2024.100515 · Cited by 12
Tsitsi, T., Polychronis, G., Papoui, E., Cloconi, C., Michail, K., & Charalambous, A. (2026) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2026.100789
Metadata
- Authors
- Krzyzanowska, M. K., Julian, J. A., Gu, C.-S., Powis, M., Li, Q., Enright, K., Howell, D., Earle, C. C., Gandhi, S., Rask, S., Brezden-Masley, C., Dent, S., Hajra, L., Freeman, O., Spadafora, S., Hamm, C., Califaretti, N., Trudeau, M., Levine, M. N., Amir, E., Bordeleau, L., Chiarotto, J. A., Elser, C., Husain, J., Laferriere, N., Rahim, Y., Robinson, A. G., Vandenberg, T., & Grunfeld, E.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2021-12-08
- Volume
- 375
- Pages
- e066588
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W4200140927
- Cited by
- 49
- References
- 8
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial. https://app.cochat.ai/papers/10.1136/bmj-2021-066588
- The paper
- Krzyzanowska, M. K., Julian, J. A., Gu, C.-S., Powis, M., Li, Q., Enright, K., Howell, D., Earle, C. C., Gandhi, S., Rask, S., Brezden-Masley, C., Dent, S., Hajra, L., Freeman, O., Spadafora, S., Hamm, C., Califaretti, N., Trudeau, M., Levine, M. N., . . . Grunfeld, E. (2021). Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial. BMJ. https://doi.org/10.1136/bmj-2021-066588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.